Search Results - Luisa Manning

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6 by Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, John Nemunaitis

    Published in Vaccines (2021-10-01)
    Get full text
    Article


  2. 2

    KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. by Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, William Maltese, Luisa Manning, Neil Senzer, John Nemunaitis

    Published in PLoS ONE (2018-01-01)
    Get full text
    Article


  3. 3

    Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer by Rodney P. Rocconi, Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam Walter, John Nemunaitis

    Published in Vaccines (2021-08-01)
    Get full text
    Article


  4. 4

    Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (202... by Jonathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

    Published in Gynecologic Oncology Reports (2021-05-01)
    Get full text
    Article


  5. 5

    ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer by Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis

    Published in Communications Medicine (2022-08-01)
    Get full text
    Article


  6. 6

    Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer by Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis

    Published in Communications Medicine (2023-05-01)
    Get full text
    Article


Search Tools: